Your metro playbook won’t work in Warangal

Last reviewed 23 September 2026

Private equity has put about Rs 8,768 crore into regional multispecialty hospitals since 2024, according to Medical Buyer. The money is chasing real demand outside the metros. But the way patients in these cities find and choose a hospital is different, and most metro marketing playbooks will not travel.

What happened

Medical Buyer reported that investment in regional hospital hubs reached Rs 4,517 crore in 2025, nearly 25% higher than 2024, taking the total since 2024 to about Rs 8,768 crore. Citing Avendus, it noted that more than 40% of private equity money in healthcare since 2019 has gone into single-specialty chains such as IVF, oncology, nephrology and eye care, up from about 15% in 2015 to 2018. Policybazaar data in the same piece shows the share of health and life premiums coming from outside the metros rising to 47% in FY25.

My take

The capital is following a real shift. Families in tier-2 and tier-3 cities are insured in greater numbers, more willing to spend on quality and less willing to travel to a metro for treatment they can get closer to home. That is good for patients and a sound bet for investors.

The risk is on the demand side. When a chain enters a new regional city, the default is to copy what worked in the metro: English-language search campaigns, a polished website, a few hoardings and some doctor profiles. In my experience that approach overspends and underdelivers outside the big cities.

How patients actually choose

• Language. Research, questions and trust happen in the local language. An English landing page is a barrier, not a signal of quality.
• Video over text. Regional YouTube and short video are often the first place a family hears a doctor explain a condition.
• WhatsApp as the front door. People forward a doctor’s video to a family group before anyone searches for the hospital.
• Referrers matter more. Local general practitioners, pharmacists, diagnostic centres and even community leaders shape the decision far more than in metros.
• Reputation is personal. Families want to know which doctor, not which brand. The hospital name comes second.

What most coverage missed

Single-specialty chains have a built-in advantage here. An IVF or eye-care brand can build a tight, repeatable content and referral model and roll it city by city. A multispecialty hospital entering the same city has to build trust across dozens of specialties at once, which is far harder and more expensive.

That means regional multispecialty operators need to choose where to lead. Pick the three or four specialties where the local gap is largest, build deep regional-language content and referral relationships around those doctors, and let the brand grow from there.

What I would do in the first ninety days

• Map the referral ecosystem before spending on media. Who sends patients today, and why?
• Produce doctor-led explainer videos in the local language for the lead specialties.
• Set up a WhatsApp channel with templates in the local language and a same-day callback promise.
• Localise the Google Business Profile, including photos, timings, directions and replies to reviews in the local language.
• Measure cost per consultation by channel from week one, so you can cut what does not work quickly.

What to watch

The investors will judge these deals on occupancy and margins. The operators who win will be the ones who treat regional demand as its own market, with its own language, channels and trust signals. The hospital is new in town. The way people choose is not.

For the full argument on what these deals change for brands, patients and data, read What hospital consolidation really buys.

Go deeper: Tier-2 city expansion: what the digital footprint tells you first, Local search for hospitals: winning “near me” across every unit and Domestic medical travel from smaller cities: the digital path.

Source: Medical Buyer. Figures as reported at the time of writing.

Questions people ask